-
Product Insights
NewQuarterly Processed Snacks pricing trends in the United Arab Emirates
Empower your strategies with our Quarterly Processed Snacks pricing trends in the United Arab Emirates report and make more profitable business decisions. Consumers’ preferences for stores are most heavily influenced by pricing and promotions, but brands and retailers continue to adjust prices and promotions based on insufficient information from expensive, drawn-out, and incomplete audits of rival techniques. Brands and retailers can benefit from the unique intelligence provided by GlobalData Ecommerce Price Tracker, covering millions of SKUs, to identify, anticipate, and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cannabidiol in Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cannabidiol in Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cannabidiol in Pain Drug Details: Xativa is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cannabidiol in Anxiety Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cannabidiol in Anxiety Disorders report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cannabidiol in Anxiety Disorders Drug Details: Xativa is under development for the...
-
Product Insights
NewTremor – Drugs In Development, 2024
Empower your strategies with our Tremor – Drugs In Development, 2024 report and make more profitable business decisions. Tremor is a neurological condition characterized by involuntary shaking or trembling movements in various body parts, primarily the hands but potentially affecting the arms, legs, head, vocal cords, and trunk, as a result of uncontrollable muscle contractions. Its impact varies, causing intermittent or constant challenges in daily tasks like writing, typing, eating, and dressing. While not life-threatening, severe cases can lead to disabilities....
-
Product Insights
NewInsomnia – Drugs In Development, 2024
Empower your strategies with our Insomnia – Drugs In Development, 2024 report and make more profitable business decisions. Insomnia is a sleep disorder that is characterized by difficulty falling and/or staying asleep. Symptoms include difficulty falling asleep at night, irritability, depression or anxiety, tension headaches, and distress in the stomach and intestines. Risk factors include age, mental health disorder, stress, and shift working. The Insomnia drugs in development market research report provide comprehensive information on the therapeutics under development for Insomnia,...
-
Product Insights
NewDyskinesia – Drugs In Development, 2024
Empower your strategies with our Dyskinesia – Drugs In Development, 2024 report and make more profitable business decisions. Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing, and tongue thrusting. The disease can be controlled by healthy life style and medication. The Dyskinesia drugs in development market research report provide comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Double Negative T Cells in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Double Negative T Cells in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Double Negative T Cells in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PBF-677 in Eosinophilic Esophagitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PBF-677 in Eosinophilic Esophagitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PBF-677 in Eosinophilic EsophagitisDrug Details:PBF-677 is under development for the treatment of ulcerative...
-
Product Insights
Insomnia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Insomnia is a sleep disorder that is characterized by difficulty falling and/or staying asleep. Symptoms include difficulty falling asleep at night, irritability, depression or anxiety, tension headaches, and distress in the stomach and intestines. Risk factors include age, mental health disorders, stress, and shift working. The Insomnia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Insomnia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and...
-
Product Insights
Dyskinesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movements. Its symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing, and tongue thrusting. However, the disease can be controlled by a healthy lifestyle and medication. The Dyskinesia pipeline market research report provides comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The...